Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Geodon

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Head-to-head study results of Geodon (ziprasidone) vs. Lilly's Zyprexa (olanazapine) presented May 8 at the American Psychiatric Association annual meeting show comparable efficacy for Geodon and Zyprexa in alleviating psychotic symptoms, but a better safety profile in terms of weight gain, cholesterol, triglycerides and insulin levels, Pfizer says. In the double-blind, six-week study of 269 hospitalized patients with schizophrenia and schizoaffective disorder, median weight gain for Geodon patients was less than 1 1b. compared to more than 10.4 lbs. for Zyprexa patients. Total cholesterol change for Geodon patients was -1 mg/dL, while Zyprexa patients' cholesterol increased by an average of 20 mg/dL. Insulin levels for Geodon patients increased 0.3 vs. 3.3 for Zyprexa. Geodon was approved Feb. 5 for treatment of schizophrenia

You may also be interested in...

Does Polivy Provide A Cure For DLBCL? Too Early To Say, Argue NICE Experts

Roche receives initial knockback for lymphoma treatment which could rival CAR-T therapies.

Back With A Bang: ‘Brexit Bill’ For UK’s Medical Devices Due For 2nd Reading On 2 March

Parliamentary debate next week on the post-Brexit regulatory adjustments ahead for the UK medical devices industry will coincide with the opening of post-Brexit EU trade talks by the UK government. After a period of nervous calm, Brexit will be back with a bang.

EU Funding For COVID-19 Drug & Diagnostic Research

Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts